SKINOXY CAPS
Food supplement declared in France, declaration No 2020-2-896, decision dated 27 February 2020
SKINOXY CAPS (BIOLISSIME) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- BIOLISSIME
- Food business operator placing the product on the market
- BIOLISSIME PARIS
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 Gélule par jour à avaler avec de l'eau
- Directions for use
- 1 gélule par jour à avaler avec de l'eau
- Not recommended (according to the manufacturer)
- Breastfeeding women, Young children (aged 1 to 3), Pregnant women, Infants (under 1 year)
Declaration 300666, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Pinus pinaster Aiton | Ecorce | Extrait sec hydroalcoolique | 50 mg |
| Morus alba L. | Fruit | Extrait sec hydroalcoolique | 2 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Collagène marin | not declared |
| Glutathion | not declared |
| Cystéine | not declared |
| Ubiquinone | not declared |
| Moule perlière d eau douce | not declared |
| Acide lipoïque | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Acide nicotinique | Acide nicotinique (vitamine B3) | 10 mg | 8 mg |
| Acide L-ascorbique | Vitamine C | pas de limite (données insuffisantes) | 180 mg |
| Cholécalciférol | Vitamine D | 100 µg (4,000 UI) | 5 µg (200 UI) |
| D-alpha-tocophérol | Vitamine E | 300 mg | 30 mg |
| Bisglycinate de zinc | Zinc | 25 mg | 15 mg |
Other ingredients
Gélule végétale
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ubiquinone
Read the warning, when it applies and the studies cited
Coenzyme Q10 (UBIQUINONE-10)
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).
Sources cited by Health Canada (2)
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
Applies to products providing more than 100 mg of Coenzyme Q10 per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (3)
- Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
- Acide lipoïque
Read the warning, when it applies and the studies cited
DL-ALPHA-LIPOIC ACID/R-ALPHA-LIPOIC ACID
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Jacob et al. 1999, Konrad et al. 1999, Packer et al. 1995).
Sources cited by Health Canada (3)
- Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology & Medicine 1999;27(3-4):309-314. PubMed Randomised trial
- Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-287. PubMed
- Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-250. PubMed Review article
Applies to products providing 42 milligrams or more DL-alpha-lipoic acid or 21 milligrams or more R-alpha-lipoic acid, per day.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience sweating, paleness, chills, headache, dizziness and/or confusion (as these may be symptoms of serious low blood sugar) (Bae et al., 2013; Gullo et al., 2014; Bresciani et al., 2011; Chang et al., 2009).
Sources cited by Health Canada (4)
- Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH. Recurrent Insulin Autoimmune Syndrome Caused by α-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013;28(4):326-330. PubMed
- Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by α-lipoic acid in a Caucasian woman: case report. Diabetes Care. 2011 Sep;34(9):e146. doi: 10.2337/dc11-0600. DOI
- Chang HJ, Choi HS, Park MY, Leem SM, Jang YS, Park KS, Lee JM. A case of insulin autoimmune syndrome related to alpha-lipoic acid. Korean J Med 2009;76:600-604.
- Gullo D, Evans JL, Sortino G, Ira D. Goldfine and Vigneri R. Insulin autoimmune syndrome (Hirata Disease) in European Caucasians taking a-lipoic acid. Clinical Endocrinology 2014;81: 204-209. PubMed
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- SKINOXY CAPS BIOLISSIME, declared in 2026 : different composition: 4 ingredient(s) added, 6 missing
Brand : BIOLISSIME
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.